Combination Latency Reversal With High Dose Disulfiram Plus Vorinostat in HIV-infected Individuals on ART
Status:
Terminated
Trial end date:
2019-04-09
Target enrollment:
Participant gender:
Summary
Antiretroviral therapy (ART) dramatically reduces Human Immunodeficiency Virus (HIV)
replication leading to restoration of immune function and a near normal life expectancy, but
treatment is lifelong and there is no cure. The major barrier to a cure is the persistence of
long lived cluster of differentiation 4 (CD4+) T-cells that contain a "silenced" form of HIV,
called HIV latency.
The purpose of this research is to investigate whether it may be possible to reduce the
amount of dormant HIV infection in immune cells, by "turning on" or activating the virus and
hence force it out of the latently infected memory T cells. This leads to production of HIV
by the cell, which will either die or will be recognized and eliminated by the immune system.
As very few T cells are latently infected with HIV, the death of these cells is not expected
to affect the function of the immune system and further infection of new cells is expected to
be prevented by ART.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
The Peter Doherty Institute for Infection and Immunity University of Melbourne
Collaborators:
Merck Sharp & Dohme Corp. The Alfred University of Melbourne